Navigation Links
Updated Survival Data from Study Comparing TTF™ (Tumor Treating Fields) Therapy to Best Standard Chemotherapy for Recurrent Glioblastoma Reported at the 16th Annual Scientific Meeting of the Society for NeuroOncology
Date:11/21/2011

ANAHEIM, Calif., Nov. 21, 2011 /PRNewswire/ -- Novocure™, a commercial stage private oncology company, announced today that Dr. Eric T. Wong, Co-Director, Brain Tumor Center, Beth Israel Deaconess Medical Center in Boston, presented follow-up results of a study focusing on overall survival in patients with recurrent glioblastoma multiforme (GBM). The long-term follow-up results from the Phase III EF-11 study compared overall survival at two and three years after initiating therapy in patients with recurrent GBM who were treated with Tumor Treating Fields™ (TTF) therapy versus best standard of care chemotherapy. The results were presented at the 16th Annual Scientific Meeting of the Society for NeuroOncology in Anaheim.

The presentation described the updated survival data two years after completing recruitment of a study comparing either continuous TTF monotherapy (20-24 hours per day, 7 days a week) or best standard of care chemotherapy based on physician choice. The primary endpoint of the Phase III study was overall survival and secondary endpoints were PFS6, radiological response rate and quality of life. The study was conducted at 28 U.S. and European-based centers.

With a median follow-up of 39 months, overall survival in the TTF group compared to the best standard of care chemotherapy group at two and three years of follow-up was 9% vs. 7% and 8% vs. 1%, respectively ( p=ns). The study also showed trends in favor of TTF compared to chemotherapy in PFS6 (21.4% vs. 15.2%, respectively, p=ns) and radiological response rates (14.0% vs. 9.6%, respectively, p=ns). Finally, patients in the TTF group had many less grade 2 or higher side effects and their quality of life was better than patients receiving chemotherapy.

"We are pleased to report that TTF therapy, a non-invasive, novel cancer treatment modality showed impressive therapeutic efficacy with promising long-term survival results in our patients, "said Dr. Wong. "We are encouraged by our findings that TTF therapy will find a critical role in the treatment of patients with recurrent GBM."

"The results of this long term follow up continue to validate the promise that NovoTTF™ therapy provides to the thousands of patients who suffer from recurrent GBM," said Asaf Danziger, CEO of Novocure. "We will continue to investigate the potential of this innovative treatment in other types of solid tumor cancers and look forward to sharing our results with the medical community in the future."

About Glioblastoma

Glioblastoma multiforme (GBM) is the most aggressive and most common form of primary brain tumor in the U.S. The disease affects approximately 10,000 Americans each year. The median overall survival time from initial diagnosis is 15 months with optimal treatment, and median survival from the time of tumor recurrence is only 3-5 months without additional effective treatment. The disease is widely recognized as one of the most aggressive and deadly forms of cancer.

About the NovoTTF-100A System™

NovoTTF-100A System™ is a portable, non-invasive medical device designed for continuous use throughout the day by the patient. The device has been shown in in vitro and in vivo studies to slow and reverse tumor growth by inhibiting mitosis, the process by which cells divide and replicate. The NovoTTF-100A device, which weighs about six pounds (three kilograms), creates a low intensity, alternating electric field within the tumor that exerts physical forces on electrically charged cellular components, preventing the normal mitotic process and causing cancer cell death prior to division. In patients with recurrent glioblastoma brain tumors, the device has shown clinical efficacy comparable to that of active chemotherapies with better quality of life without many of the side effects of chemotherapy. The NovoTTF-100A has received marketing approval in the US and is a CE Marked device that is cleared for sale in Europe.

The US Food and Drug Administration (FDA) has approved the NovoTTF-100A System for use as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM), following histologically – or radiologically-confirmed recurrence in the supra-tentorial region of the brain after receiving chemotherapy. The device is intended to be used as monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.

Patients should only use the NovoTTF-100A System under the supervision of a physician properly trained in use of the device.

About Novocure™

Novocure™ Limited is a private oncology company pioneering a novel therapy for solid tumors. Novocure's worldwide headquarters is located in the Jersey Isle. Novocure's US operations are based in Portsmouth, NH and the company's research center is located in Haifa, Israel. For additional information about the company, please visit www.novocure.com.

Disclosure Statement

Dr. Eric T. Wong received research grants from Novocure, Inc. He has complete access to the research data from the EF-11 clinical trial and the results of the data analysis.


'/>"/>
SOURCE Novocure
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. DEXILANT (dexlansoprazole) Product Information Updated Regarding Coadministration with Plavix (clopidogrel bisulfate)
2. K-V Pharmaceutical Announces Updated Makena® Performance Metrics
3. Updated Hepatitis C Practice Guidelines Now Available from AASLD
4. Delcath Announces Updated Efficacy Results From Phase 3 Trial of Chemosaturation for Melanoma Metastases in the Liver Presented at European Multidisciplinary Cancer Congress
5. Updated: Teikoku Pharma USA, Inc. and Verde Environmental Technologies, Inc. Announce Licensing Agreement for Pharmaceutical Disposal Technology
6. Questcor Provides Updated New Paid Prescription Trends
7. Cepheid Announces Release of Updated Xpert BCR-ABL Monitor Test
8. Onyx Pharmaceuticals Announces Updated Pivotal Carfilzomib Phase 2B Data
9. Neuro Kinetics Releases Updated Version of Neuro-Otologic Control and Analysis Software
10. FDA Approves Updated, Clarified Indication for Use for iFuse Implant System®
11. TPI Business and Development Profile Updated on OneMedDatabase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ROCKVILLE, Md. , March 28, 2017 /PRNewswire/ ... dedicated to innovative therapeutics addressing cancer and other ... at the American Association for Cancer Research annual ... April 3 is entitled "Evaluation of ENMD-2076 ... and the second poster to be presented ...
(Date:3/28/2017)... Elysium Health joins major pharmaceutical ... Cambridge academic scientists through ... Milner Therapeutics Institute today announces Elysium Health as a partner ... investment for collaborative projects with academic researchers in ... the first major research investment outside the U.S. for the ...
(Date:3/27/2017)... WAUKESHA, Wis. , March 27, 2017  A ... one of only four freestanding hospitals in the country ... in plastic and reconstructive surgery, concluded that the Surfacide ... effective and integral component in reducing bacterial pathogens not ... The findings were published at the American Burn Association,s ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... WHO: , Dr. Paul ... , WHAT: , Medical doctors and PhD scientists will speak to the press on ... Trump in support of an independent vaccine safety commission. , WHERE: , Zenger ...
(Date:3/28/2017)... ... March 28, 2017 , ... Qualidigm ... its corporate headquarters to a new, more expansive office space in order to ... Qualidigm purchased a distressed office building in Wethersfield, Conn. located at 936 Silas ...
(Date:3/28/2017)... ... 28, 2017 , ... The Executives, Staff & Clients of MGE: Management Experts ... for Tots Literacy Campaign at their Semi-Annual Graduation and Fundraiser Event at MGE’s St. ... ranks at number 14 internationally in literacy. Statistically, a direct relation can be a ...
(Date:3/28/2017)... , ... March 28, 2017 , ... Public relations pros ... across a variety of business channels. , While many results are clear, much of ... relations program. , When it comes to measurement, firms should always take an ...
(Date:3/28/2017)... ... March 28, 2017 , ... Thank you to all who attended ... , This event was exclusive to providers and offered an opportunity to collaborate ... place at the Manchester Grand Hyatt where attendees gathered for a lively discussion on ...
Breaking Medicine News(10 mins):